

OPEXA THERAPEUTICS, INC.

FORM 8-K (Current report filing)

Filed 06/16/06 for the Period Ending 06/16/06

Address	2635 TECHNOLOGY FOREST BLVD. THE WOODLANDS, TX 77381
Telephone	(281) 272-9331
CIK	0001069308
Symbol	OPXA
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

UNITED STATES
SECURITIES EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2006

PHARMAFRONTIERS CORP.

(Exact name of registrant as specified in its charter)

Texas	000-25513	76-0333165
-----	-----	-----
(State of organization)	(Commission File Number)	(IRS Employer Identification No.)
2635 N. Crescent Ridge Drive		
The Woodlands, Texas		77381
-----		-----
(Address of principal executive offices)		(Zip Code)

Registrant's Telephone Number, including area code: (281) 272-9331

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Election of Directors

On June 15, 2006, the board of directors appointed Michael Richman to the Board of Directors. Mr. Richman was also appointed to the board's audit, compensation and nominating committees.

Michael S. Richman, MSBA., is executive vice president and chief operating officer of MacroGenics, Inc. located in Rockville, MD. He joined the firm in 2002 with over twenty years experience in corporate business development within the biotechnology industry. Before joining MacroGenics Inc, he was senior vice president, corporate development administration at MedImmune, Inc. from 1996 to 2002. From 1985 to 1996, Mr. Richman served in various senior positions at Chiron Corporation, a public biotechnology company, with his last position being director of corporate business development. His previous positions include: manager of business development, from 1990 to 1992 and manager of intellectual property from 1988 to 1990. Mr. Richman also serves on the board of directors of Cougar Biotechnology, Inc., a publicly traded biotechnology company.

Mr. Richman has not been involved with a related transaction or relationship as defined by Item 404(a) of Regulation S-B with the Company.

Item 9.01 Financial Statements and Exhibit

(c) Exhibits

The following exhibits are to be filed as part of this 8-K:

Exhibit No. -----	Identification of Exhibit -----
99.1	Press Release dated June 16, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMAFRONTIERS CORP.

By: */s/ David McWilliams*

David McWilliams, Chief Executive Officer

DATE: *June 16, 2006*

EXHIBIT INDEX

Exhibit No. -----	Description -----
99.1	Press Release dated June 16, 2006

PharmaFrontiers Appoints Michael Richman to Board of Directors

THE WOODLANDS, Texas--(BUSINESS WIRE)--June 16, 2006--PharmaFrontiers (OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, today announced the appointment of Michael Richman to PharmaFrontiers' board of directors. Mr. Richman will also serve on the board's audit, compensation and nominating committees.

David B. McWilliams, chief executive officer of PharmaFrontiers, commented, "We are very pleased to welcome Michael to our expanding board of directors. I believe his vast experience in managing strategic partnerships and agreements, as well as his expertise in all aspects of corporate development, will play a significant role in helping push forward the Company's growth strategy."

Michael S. Richman, MSBA

Michael S. Richman, MSBA, is executive vice president and chief operating officer of MacroGenics, Inc. located in Rockville, MD. He joined the firm in 2002 with over twenty years experience in corporate business development within the biotechnology industry. Before joining MacroGenics Inc., he was senior vice president, corporate development administration at MedImmune, Inc. (1996 - 2002). From 1985 -1996, Mr. Richman served in various senior positions at Chiron Corporation, a public biotechnology company, with his last position being director of corporate business development. His previous positions include:

manager of business development, (1990-1992) and manager of intellectual property (1988-1990).

Along with comprehensive experience in corporate development, Mr. Richman brings to the board of directors an extensive involvement in strategic management, encompassing legal affairs, licensing and project management and a strong knowledge of U.S. and foreign intellectual property systems.

He holds a MSBA degree from San Francisco State University with a concentration in International Business, and a B.S. degree from the University of California at Davis.

About PharmaFrontiers

PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as multiple sclerosis, rheumatoid arthritis, pancreatic and cardiac conditions. PharmaFrontiers has exclusive license from Baylor College of Medicine for individualized cell therapies that has initiated a FDA Phase IIb clinical trial to evaluate effectiveness in treating MS. The company also holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences of the People's Republic of China. The company also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: PharmaFrontiers Corp.

Lynne Hohlfeld, 281-719-3421

lhohlfeld@pharmafrontierscorp.com or
Investor Relations:

Lippert/Heilshorn & Associates

Kim Sutton Golodetz, 212-838-3777 kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com